IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 228 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,024,750 | +343.1% | 445,000 | +584.6% | 0.68% | +390.6% |
| Q2 2023 | $456,950 | +33.8% | 65,000 | +16.1% | 0.14% | +46.3% |
| Q1 2023 | $341,600 | -4.4% | 56,000 | 0.0% | 0.10% | -13.6% |
| Q4 2022 | $357,280 | -33.3% | 56,000 | 0.0% | 0.11% | -36.0% |
| Q3 2022 | $536,000 | -99.8% | 56,000 | +1759.8% | 0.17% | -94.0% |
| Q2 2022 | $273,000,000 | +9526.2% | 3,011 | -94.8% | 2.85% | +345.0% |
| Q1 2022 | $2,836,000 | +156.4% | 58,000 | 0.0% | 0.64% | +160.2% |
| Q4 2021 | $1,106,000 | -22.7% | 58,000 | 0.0% | 0.25% | -28.7% |
| Q3 2021 | $1,430,000 | -5.2% | 58,000 | 0.0% | 0.34% | -13.3% |
| Q2 2021 | $1,509,000 | -17.8% | 58,000 | 0.0% | 0.40% | -18.1% |
| Q1 2021 | $1,836,000 | -31.8% | 58,000 | 0.0% | 0.49% | -33.9% |
| Q4 2020 | $2,693,000 | -43.6% | 58,000 | -60.0% | 0.74% | -52.3% |
| Q3 2020 | $4,773,000 | +87.7% | 145,000 | +39.4% | 1.54% | +63.4% |
| Q2 2019 | $2,543,000 | – | 104,000 | – | 0.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |